2. What this study adds:
- We propose a model-based approach for hydroxychloroquine dose
rationale with clinical validation using literature pharmacokinetic data
in autoimmune disease and COVID-19.
- Clinical efficacy and safety data in COVID-19 patients are used for
contextualization.
- Uncertainties and gaps are identified as well as data needed to
address them.